Dr Jennifer Martin Discusses How Insomnia Has Evolved & Affects In Insurance Coverage
In this video, Jennifer Martin, PhD, Assistant Professor, UCLA, David School of Medicine, shares her thoughts on how non-pharmacologic treatments for the management of insomnia has evolved over the past few years and how the increased use of behavioral treatments might affect insurance coverage.
This video was taken on June 3, 2013, at the Sleep 2013 Conference in Baltimore, MD.
Accountable care organizations (ACOs) are still a new creature in the world of managed care, and not all are alike. As the authors of a new comparative analysis in The American Journal of Managed Care outline, Medicare contracts dominate the ACO landscape, with only half of these entities having a contract with a private payer.
The falling uninsured rate among all racial/ethnic groups under current Medicaid expansion decisions will narrow coverage differences between whites and all minority groups except for blacks, according to a report from the Urban Institute.
The FDA today granted accelerated approval to olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, for treatment of advanced ovarian cancer in women with defected BRCA genes, along with a companion diagnostic test that marked the agency’s first approval of a laboratory developed test (LDT) under a premarket approval application.
The panelists get to say their final remarks, and while they are all optimistic about the direction mental healthcare in the United States is heading, they all acknowledge the change is slow and more work is left to be done.